Lupin has received a 505 (b) (2) NDA approval for its Nikita (Pitavastatin) Tablets 1 mg, 2 mg and 4 mg from the United States Food and Drug Administration (USFDA).
Lupin’s Nikita (Pitavastatin) Tablets 1 mg, 2 mg and 4 mg are Pitavastatin Sodium, an alternate salt product of Kowa Company’s Livalo (Pitavastatin Calcium) Tablets. It is a new option for patients with primary hyperlipidemia or mixed dyslipidemia as an adjunctive therapy to diet to reduce elevated total cholesterol, low-density lipoprotein cholesterol, apolipoprotein B, triglycerides and to increase high-density lipoprotein cholesterol. Livalo Tablets had US sales of $272 million, as per IMS MAT June 2017.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1877.45 |
| Dr. Reddys Lab | 1290.00 |
| Cipla | 1332.00 |
| Zydus Lifesciences | 945.20 |
| Lupin | 2256.50 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: